143 related articles for article (PubMed ID: 35663326)
21. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.
Orucevic A; Chen J; McLoughlin JM; Heidel RE; Panella T; Bell J
Breast J; 2015; 21(2):147-54. PubMed ID: 25600504
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
[TBL] [Abstract][Full Text] [Related]
24. LAT1 (SLC7A5) Overexpression in Negative Her2 Group of Breast Cancer: A Potential Therapy Target.
Bodoor K; Almomani R; Alqudah M; Haddad Y; Samouri W
Asian Pac J Cancer Prev; 2020 May; 21(5):1453-1458. PubMed ID: 32458655
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
26. Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
Wu H; Guan S; Sun M; Yu Z; Zhao L; He M; Zhao H; Yao W; Wang E; Jin F; Xiao Q; Wei M
PLoS One; 2015; 10(5):e0126128. PubMed ID: 25961581
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
28. 6-lncRNA Assessment Model for Monitoring and Prognosis of HER2-Positive Breast Cancer: Based on Transcriptome Data.
Zhang X; Zhang H; Li J; Ma X; He Z; Liu C; Gao C; Li H; Wang X; Wu J
Pathol Oncol Res; 2021; 27():609083. PubMed ID: 34257572
[No Abstract] [Full Text] [Related]
29. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
30. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
31. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
32. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
33. Key Genes and Prognostic Analysis in HER2+ Breast Cancer.
Weng Y; Liang W; Ji Y; Li Z; Jia R; Liang Y; Ning P; Xu Y
Technol Cancer Res Treat; 2021; 20():1533033820983298. PubMed ID: 33499770
[TBL] [Abstract][Full Text] [Related]
34. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
Fan Y; Wang Y; He L; Imani S; Wen Q
ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
[TBL] [Abstract][Full Text] [Related]
35. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
36.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
37. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
[TBL] [Abstract][Full Text] [Related]
38. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
39. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
40. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
Schmidt G; Meyberg-Solomayer G; Gerlinger C; Juhasz-Böss I; Herr D; Rody A; Liedtke C; Solomayer EF
Arch Gynecol Obstet; 2014 Dec; 290(6):1221-9. PubMed ID: 25012601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]